nodes	percent_of_prediction	percent_of_DWPC	metapath
Methylnaltrexone—CYP2D6—Formoterol—chronic obstructive pulmonary disease	0.268	0.346	CbGbCtD
Methylnaltrexone—CYP2D6—Arformoterol—chronic obstructive pulmonary disease	0.268	0.346	CbGbCtD
Methylnaltrexone—CYP2D6—Tiotropium—chronic obstructive pulmonary disease	0.239	0.308	CbGbCtD
Methylnaltrexone—Naloxone—TLR4—chronic obstructive pulmonary disease	0.0117	0.745	CrCbGaD
Methylnaltrexone—Unspecified disorder of skin and subcutaneous tissue—Roflumilast—chronic obstructive pulmonary disease	0.00522	0.025	CcSEcCtD
Methylnaltrexone—Nervous system disorder—Roflumilast—chronic obstructive pulmonary disease	0.00494	0.0237	CcSEcCtD
Methylnaltrexone—Skin disorder—Roflumilast—chronic obstructive pulmonary disease	0.0049	0.0234	CcSEcCtD
Methylnaltrexone—Stinging—Prednisolone—chronic obstructive pulmonary disease	0.00479	0.0229	CcSEcCtD
Methylnaltrexone—Gastrointestinal disorder—Roflumilast—chronic obstructive pulmonary disease	0.00435	0.0208	CcSEcCtD
Methylnaltrexone—Gastrointestinal pain—Roflumilast—chronic obstructive pulmonary disease	0.00412	0.0197	CcSEcCtD
Methylnaltrexone—Abdominal pain—Roflumilast—chronic obstructive pulmonary disease	0.00398	0.0191	CcSEcCtD
Methylnaltrexone—Diarrhoea—Roflumilast—chronic obstructive pulmonary disease	0.00345	0.0165	CcSEcCtD
Methylnaltrexone—Dizziness—Roflumilast—chronic obstructive pulmonary disease	0.00333	0.016	CcSEcCtD
Methylnaltrexone—Nervous system disorder—Aminophylline—chronic obstructive pulmonary disease	0.0033	0.0158	CcSEcCtD
Methylnaltrexone—Unspecified disorder of skin and subcutaneous tissue—Tiotropium—chronic obstructive pulmonary disease	0.00328	0.0157	CcSEcCtD
Methylnaltrexone—Vomiting—Roflumilast—chronic obstructive pulmonary disease	0.0032	0.0153	CcSEcCtD
Methylnaltrexone—Oedema—Tiotropium—chronic obstructive pulmonary disease	0.00317	0.0152	CcSEcCtD
Methylnaltrexone—Nervous system disorder—Tiotropium—chronic obstructive pulmonary disease	0.00311	0.0149	CcSEcCtD
Methylnaltrexone—Skin disorder—Tiotropium—chronic obstructive pulmonary disease	0.00308	0.0147	CcSEcCtD
Methylnaltrexone—Nausea—Roflumilast—chronic obstructive pulmonary disease	0.00299	0.0143	CcSEcCtD
Methylnaltrexone—Flatulence—Salbutamol—chronic obstructive pulmonary disease	0.00292	0.014	CcSEcCtD
Methylnaltrexone—Gastrointestinal pain—Aminophylline—chronic obstructive pulmonary disease	0.00275	0.0132	CcSEcCtD
Methylnaltrexone—Gastrointestinal disorder—Tiotropium—chronic obstructive pulmonary disease	0.00274	0.0131	CcSEcCtD
Methylnaltrexone—Abdominal pain—Aminophylline—chronic obstructive pulmonary disease	0.00266	0.0127	CcSEcCtD
Methylnaltrexone—Unspecified disorder of skin and subcutaneous tissue—Formoterol—chronic obstructive pulmonary disease	0.00265	0.0127	CcSEcCtD
Methylnaltrexone—Unspecified disorder of skin and subcutaneous tissue—Arformoterol—chronic obstructive pulmonary disease	0.00265	0.0127	CcSEcCtD
Methylnaltrexone—Unspecified disorder of skin and subcutaneous tissue—Montelukast—chronic obstructive pulmonary disease	0.0026	0.0124	CcSEcCtD
Methylnaltrexone—Gastrointestinal pain—Tiotropium—chronic obstructive pulmonary disease	0.00259	0.0124	CcSEcCtD
Methylnaltrexone—Oedema—Formoterol—chronic obstructive pulmonary disease	0.00256	0.0122	CcSEcCtD
Methylnaltrexone—Oedema—Arformoterol—chronic obstructive pulmonary disease	0.00256	0.0122	CcSEcCtD
Methylnaltrexone—Buprenorphine—CYP1A2—chronic obstructive pulmonary disease	0.00255	0.162	CrCbGaD
Methylnaltrexone—Nervous system disorder—Arformoterol—chronic obstructive pulmonary disease	0.00251	0.012	CcSEcCtD
Methylnaltrexone—Nervous system disorder—Formoterol—chronic obstructive pulmonary disease	0.00251	0.012	CcSEcCtD
Methylnaltrexone—Abdominal pain—Tiotropium—chronic obstructive pulmonary disease	0.00251	0.012	CcSEcCtD
Methylnaltrexone—Oedema—Montelukast—chronic obstructive pulmonary disease	0.00251	0.012	CcSEcCtD
Methylnaltrexone—Skin disorder—Arformoterol—chronic obstructive pulmonary disease	0.00248	0.0119	CcSEcCtD
Methylnaltrexone—Skin disorder—Formoterol—chronic obstructive pulmonary disease	0.00248	0.0119	CcSEcCtD
Methylnaltrexone—Nervous system disorder—Montelukast—chronic obstructive pulmonary disease	0.00246	0.0118	CcSEcCtD
Methylnaltrexone—Skin disorder—Montelukast—chronic obstructive pulmonary disease	0.00243	0.0116	CcSEcCtD
Methylnaltrexone—Oedema—Salbutamol—chronic obstructive pulmonary disease	0.00242	0.0116	CcSEcCtD
Methylnaltrexone—Nervous system disorder—Salbutamol—chronic obstructive pulmonary disease	0.00237	0.0113	CcSEcCtD
Methylnaltrexone—Skin disorder—Salbutamol—chronic obstructive pulmonary disease	0.00235	0.0112	CcSEcCtD
Methylnaltrexone—Hyperhidrosis—Salbutamol—chronic obstructive pulmonary disease	0.00234	0.0112	CcSEcCtD
Methylnaltrexone—Diarrhoea—Aminophylline—chronic obstructive pulmonary disease	0.0023	0.011	CcSEcCtD
Methylnaltrexone—Dizziness—Aminophylline—chronic obstructive pulmonary disease	0.00222	0.0106	CcSEcCtD
Methylnaltrexone—Gastrointestinal disorder—Arformoterol—chronic obstructive pulmonary disease	0.00221	0.0106	CcSEcCtD
Methylnaltrexone—Gastrointestinal disorder—Formoterol—chronic obstructive pulmonary disease	0.00221	0.0106	CcSEcCtD
Methylnaltrexone—Pain—Arformoterol—chronic obstructive pulmonary disease	0.00219	0.0105	CcSEcCtD
Methylnaltrexone—Pain—Formoterol—chronic obstructive pulmonary disease	0.00219	0.0105	CcSEcCtD
Methylnaltrexone—Gastrointestinal disorder—Montelukast—chronic obstructive pulmonary disease	0.00216	0.0104	CcSEcCtD
Methylnaltrexone—Pain—Montelukast—chronic obstructive pulmonary disease	0.00214	0.0103	CcSEcCtD
Methylnaltrexone—Vomiting—Aminophylline—chronic obstructive pulmonary disease	0.00214	0.0102	CcSEcCtD
Methylnaltrexone—Dizziness—Tiotropium—chronic obstructive pulmonary disease	0.0021	0.01	CcSEcCtD
Methylnaltrexone—Gastrointestinal pain—Formoterol—chronic obstructive pulmonary disease	0.00209	0.01	CcSEcCtD
Methylnaltrexone—Gastrointestinal pain—Arformoterol—chronic obstructive pulmonary disease	0.00209	0.01	CcSEcCtD
Methylnaltrexone—Gastrointestinal disorder—Salbutamol—chronic obstructive pulmonary disease	0.00209	0.00998	CcSEcCtD
Methylnaltrexone—Pain—Salbutamol—chronic obstructive pulmonary disease	0.00207	0.00989	CcSEcCtD
Methylnaltrexone—Gastrointestinal pain—Montelukast—chronic obstructive pulmonary disease	0.00205	0.00981	CcSEcCtD
Methylnaltrexone—Abdominal pain—Arformoterol—chronic obstructive pulmonary disease	0.00202	0.00968	CcSEcCtD
Methylnaltrexone—Abdominal pain—Formoterol—chronic obstructive pulmonary disease	0.00202	0.00968	CcSEcCtD
Methylnaltrexone—Vomiting—Tiotropium—chronic obstructive pulmonary disease	0.00202	0.00965	CcSEcCtD
Methylnaltrexone—Nausea—Aminophylline—chronic obstructive pulmonary disease	0.002	0.00956	CcSEcCtD
Methylnaltrexone—Abdominal pain—Montelukast—chronic obstructive pulmonary disease	0.00198	0.00948	CcSEcCtD
Methylnaltrexone—Gastrointestinal pain—Salbutamol—chronic obstructive pulmonary disease	0.00198	0.00945	CcSEcCtD
Methylnaltrexone—Abdominal pain—Salbutamol—chronic obstructive pulmonary disease	0.00191	0.00914	CcSEcCtD
Methylnaltrexone—Nausea—Tiotropium—chronic obstructive pulmonary disease	0.00188	0.00901	CcSEcCtD
Methylnaltrexone—Diarrhoea—Formoterol—chronic obstructive pulmonary disease	0.00175	0.00838	CcSEcCtD
Methylnaltrexone—Diarrhoea—Arformoterol—chronic obstructive pulmonary disease	0.00175	0.00838	CcSEcCtD
Methylnaltrexone—Diarrhoea—Montelukast—chronic obstructive pulmonary disease	0.00171	0.00821	CcSEcCtD
Methylnaltrexone—Erythema—Prednisolone—chronic obstructive pulmonary disease	0.0017	0.00813	CcSEcCtD
Methylnaltrexone—Dizziness—Arformoterol—chronic obstructive pulmonary disease	0.00169	0.0081	CcSEcCtD
Methylnaltrexone—Dizziness—Formoterol—chronic obstructive pulmonary disease	0.00169	0.0081	CcSEcCtD
Methylnaltrexone—Dizziness—Montelukast—chronic obstructive pulmonary disease	0.00166	0.00793	CcSEcCtD
Methylnaltrexone—Diarrhoea—Salbutamol—chronic obstructive pulmonary disease	0.00165	0.00791	CcSEcCtD
Methylnaltrexone—Vomiting—Arformoterol—chronic obstructive pulmonary disease	0.00163	0.00779	CcSEcCtD
Methylnaltrexone—Vomiting—Formoterol—chronic obstructive pulmonary disease	0.00163	0.00779	CcSEcCtD
Methylnaltrexone—Dizziness—Salbutamol—chronic obstructive pulmonary disease	0.0016	0.00765	CcSEcCtD
Methylnaltrexone—Vomiting—Montelukast—chronic obstructive pulmonary disease	0.00159	0.00763	CcSEcCtD
Methylnaltrexone—Vomiting—Salbutamol—chronic obstructive pulmonary disease	0.00154	0.00735	CcSEcCtD
Methylnaltrexone—Nausea—Formoterol—chronic obstructive pulmonary disease	0.00152	0.00727	CcSEcCtD
Methylnaltrexone—Nausea—Arformoterol—chronic obstructive pulmonary disease	0.00152	0.00727	CcSEcCtD
Methylnaltrexone—Nausea—Montelukast—chronic obstructive pulmonary disease	0.00149	0.00712	CcSEcCtD
Methylnaltrexone—Naloxone—ALB—chronic obstructive pulmonary disease	0.00146	0.093	CrCbGaD
Methylnaltrexone—Nausea—Salbutamol—chronic obstructive pulmonary disease	0.00143	0.00687	CcSEcCtD
Methylnaltrexone—Oedema—Prednisolone—chronic obstructive pulmonary disease	0.00139	0.00663	CcSEcCtD
Methylnaltrexone—Hyperhidrosis—Prednisolone—chronic obstructive pulmonary disease	0.00134	0.00641	CcSEcCtD
Methylnaltrexone—Erythema—Prednisone—chronic obstructive pulmonary disease	0.00123	0.0059	CcSEcCtD
Methylnaltrexone—Pain—Prednisolone—chronic obstructive pulmonary disease	0.00118	0.00567	CcSEcCtD
Methylnaltrexone—Unspecified disorder of skin and subcutaneous tissue—Prednisone—chronic obstructive pulmonary disease	0.00104	0.00499	CcSEcCtD
Methylnaltrexone—Oedema—Prednisone—chronic obstructive pulmonary disease	0.00101	0.00482	CcSEcCtD
Methylnaltrexone—Nervous system disorder—Prednisone—chronic obstructive pulmonary disease	0.000987	0.00473	CcSEcCtD
Methylnaltrexone—Skin disorder—Prednisone—chronic obstructive pulmonary disease	0.000978	0.00468	CcSEcCtD
Methylnaltrexone—Hyperhidrosis—Prednisone—chronic obstructive pulmonary disease	0.000973	0.00466	CcSEcCtD
Methylnaltrexone—Dizziness—Prednisolone—chronic obstructive pulmonary disease	0.000916	0.00439	CcSEcCtD
Methylnaltrexone—Gastrointestinal pain—Prednisone—chronic obstructive pulmonary disease	0.000823	0.00394	CcSEcCtD
Methylnaltrexone—Nausea—Prednisolone—chronic obstructive pulmonary disease	0.000823	0.00394	CcSEcCtD
Methylnaltrexone—Abdominal pain—Prednisone—chronic obstructive pulmonary disease	0.000796	0.00381	CcSEcCtD
Methylnaltrexone—Diarrhoea—Prednisone—chronic obstructive pulmonary disease	0.000689	0.0033	CcSEcCtD
Methylnaltrexone—Dizziness—Prednisone—chronic obstructive pulmonary disease	0.000666	0.00319	CcSEcCtD
Methylnaltrexone—Vomiting—Prednisone—chronic obstructive pulmonary disease	0.00064	0.00306	CcSEcCtD
Methylnaltrexone—Nausea—Prednisone—chronic obstructive pulmonary disease	0.000598	0.00286	CcSEcCtD
